A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

• Status: RECRUITING
• Trial end date: 2026-08-14

Summary

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

• Phase: PHASE2

Details

• Lead Sponsor: Janssen Research & Development, LLC
• Treatments: dupilumab